Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $3.69B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
ALKERMES USD 4.62B 333M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Biogen USD 25.82B 5.28B Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Cara Therapeutics USD 366M 338M Sep/2025
Corcept Therapeutics USD 3.66B 5.1B Dec/2025
Cytokinetics USD 7.77B 1.19B Dec/2025
Eisai JPY 1.31T 140.95B Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Incyte USD 19.39B 2.83B Dec/2025
J&J USD 500.24B 67.44B Dec/2025
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
Prothena USD 514M 11M Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025